Prescription and switching patterns of direct oral anticoagulants in patients with atrial fibrillation.
anticoagulants
atrial fibrillation
big data
drug substitution
thromboembolism
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
22
01
2024
revised:
12
07
2024
accepted:
16
07
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
The patterns of direct oral anticoagulant (DOAC) selection and switching to a different oral anticoagulant (OAC) in patients with atrial fibrillation (AF) are unknown. To describe temporal patterns in first DOAC prescriptions, estimate the incidence, and identify predictors of switching to a different OAC within 1 year in OAC-naive AF patients. In this retrospective cohort study, using a near-nationwide prescription registry (IQVIA, the Netherlands), we determined the number of patients per month initiated on each DOAC and identified predictors of switching within 1 year with robust Poisson regression. We included 94,874 patients. From November 2015 to November 2019, the monthly use of apixaban ( In the Netherlands, factor Xa inhibitors are increasingly being selected for OAC-naive AF patients. Seven percent of patients switch to a different OAC within 1 year, and the initial DOAC type and dose are strong predictors of switching.
Sections du résumé
Background
UNASSIGNED
The patterns of direct oral anticoagulant (DOAC) selection and switching to a different oral anticoagulant (OAC) in patients with atrial fibrillation (AF) are unknown.
Objectives
UNASSIGNED
To describe temporal patterns in first DOAC prescriptions, estimate the incidence, and identify predictors of switching to a different OAC within 1 year in OAC-naive AF patients.
Methods
UNASSIGNED
In this retrospective cohort study, using a near-nationwide prescription registry (IQVIA, the Netherlands), we determined the number of patients per month initiated on each DOAC and identified predictors of switching within 1 year with robust Poisson regression.
Results
UNASSIGNED
We included 94,874 patients. From November 2015 to November 2019, the monthly use of apixaban (
Conclusion
UNASSIGNED
In the Netherlands, factor Xa inhibitors are increasingly being selected for OAC-naive AF patients. Seven percent of patients switch to a different OAC within 1 year, and the initial DOAC type and dose are strong predictors of switching.
Identifiants
pubmed: 39286604
doi: 10.1016/j.rpth.2024.102544
pii: S2475-0379(24)00239-5
pmc: PMC11404132
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102544Informations de copyright
© 2024 The Author(s).